HYDERABAD: India's Bharat Biotech has come together with LLC, which is a US-based company to use their adjuvant Alhydroxiquim-II. They have signed the pact to boost the immune response and to have longer-lasting immunity of Bharat Biotech's indigenous Covaxin, the Covid-19 vaccine candidate of India. Covaxin is going through its Phase II clinical trials.
The adjuvant is a substance that is used or added in a vaccine to increase the production of antibodies and provides immunity for a longer period of time. This in return reduces the antigen dose needed for vaccination. Both companies have entered a licensing agreement for using ViroVax LLCs technology.
The Chairman and Managing Director of Bharat Biotech, Krishna Ella said that "Our partnership with ViroVax resonates with Bharat Biotech's relentless efforts towards developing safe and effective vaccines coupled with long term immunity."
Covaxin, which is an inactivated vaccinBharat Biotech partner with ViroVax for immunity building vaccines uses the SARS-CoV-2 virus strain. The strain was preserved in the National Institute of Virology (NIV), Pune. It was then formulated with the adjuvant from ViroVax to produce the vaccine candidate.